StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) stock

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30239% above fair value
$143.37−1.09 (-0.75%)

Close on Nov 17, 2026Market cap $353.72BP/E 114.7Yield 2.29%

Merck net income

Net income is the profit left for shareholders after every expense, interest and tax.

Merck's net income for the twelve months ending Jun 30, 2026 was $3.17B, down 80.7% year over year. For fiscal 2025 it was $18.25B, up 6.6% from the year before. Over ten years it grew 15.2% a year on average. The highest annual figure on record is $18.25B in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.25B+6.6%
FY2024Dec 31, 2024$17.12B+4589.6%
FY2023Dec 31, 2023$365.00M-97.5%
FY2022Dec 31, 2022$14.52B+11.3%
FY2021Dec 31, 2021$13.05B+84.6%
FY2020Dec 31, 2020$7.07B-28.2%
FY2019Dec 31, 2019$9.84B+58.2%
FY2018Dec 31, 2018$6.22B+159.8%
FY2017Dec 31, 2017$2.39B-38.9%
FY2016Dec 31, 2016$3.92B-11.8%
FY2015Dec 31, 2015$4.44B-62.7%
FY2014Dec 31, 2014$11.92B+170.7%
FY2013Dec 31, 2013$4.40B-28.6%
FY2012Dec 31, 2012$6.17B-1.7%
FY2011Dec 31, 2011$6.27B+628.5%
FY2010Dec 31, 2010$861.00M-93.3%
FY2009Dec 31, 2009$12.90B+65.2%
FY2008Dec 31, 2008$7.81B+138.4%
FY2007Dec 31, 2007$3.28B–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.34B-130.2%
Q1 FY2026Mar 31, 2026-$4.24B-183.5%
Q4 FY2025Dec 31, 2025$2.96B-20.8%
Q3 FY2025Sep 30, 2025$5.79B+83.2%
Q2 FY2025Jun 30, 2025$4.43B-18.8%
Q1 FY2025Mar 31, 2025$5.08B+6.7%
Q4 FY2024Dec 31, 2024$3.74B–
Q3 FY2024Sep 30, 2024$3.16B-33.5%
Q2 FY2024Jun 30, 2024$5.46B–
Q1 FY2024Mar 31, 2024$4.76B+68.8%
Q4 FY2023Dec 31, 2023-$1.23B-140.6%
Q3 FY2023Sep 30, 2023$4.75B+46.1%
Q2 FY2023Jun 30, 2023-$5.98B-251.5%
Q1 FY2023Mar 31, 2023$2.82B-34.5%
Q4 FY2022Dec 31, 2022$3.02B-19.7%
Q3 FY2022Sep 30, 2022$3.25B-28.9%
Q2 FY2022Jun 30, 2022$3.94B+155.3%
Q1 FY2022Mar 31, 2022$4.31B+35.6%
Q4 FY2021Dec 31, 2021$3.76B–
Q3 FY2021Sep 30, 2021$4.57B+55.3%
Q2 FY2021Jun 30, 2021$1.55B-48.5%
Q1 FY2021Mar 31, 2021$3.18B-1.2%
Q4 FY2020Dec 31, 2020-$2.09B-188.9%
Q3 FY2020Sep 30, 2020$2.94B+54.7%
Q2 FY2020Jun 30, 2020$3.00B+12.4%
Q1 FY2020Mar 31, 2020$3.22B+10.4%
Q4 FY2019Dec 31, 2019$2.36B+29.0%
Q3 FY2019Sep 30, 2019$1.90B-2.5%
Q2 FY2019Jun 30, 2019$2.67B+56.4%
Q1 FY2019Mar 31, 2019$2.92B+296.1%
Q4 FY2018Dec 31, 2018$1.83B–
Q3 FY2018Sep 30, 2018$1.95B–
Q2 FY2018Jun 30, 2018$1.71B-12.3%
Q1 FY2018Mar 31, 2018$736.00M-52.5%
Q4 FY2017Dec 31, 2017-$1.05B–
Q3 FY2017Sep 30, 2017-$56.00M-102.6%
Q2 FY2017Jun 30, 2017$1.95B–
Q1 FY2017Mar 31, 2017$1.55B–
Q4 FY2016Dec 31, 2016-$595.00M–
Q3 FY2016Sep 30, 2016$2.18B–

More Merck figures

See a number that looks wrong?